These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants. Croisier D, Etienne M, Piroth L, Bergoin E, Lequeu C, Portier H, Chavanet P. J Antimicrob Chemother; 2004 Sep; 54(3):640-7. PubMed ID: 15317743 [Abstract] [Full Text] [Related]
12. Antipneumococcal activities of gemifloxacin compared to those of nine other agents. Davies TA, Kelly LM, Pankuch GA, Credito KL, Jacobs MR, Appelbaum PC. Antimicrob Agents Chemother; 2000 Feb; 44(2):304-10. PubMed ID: 10639354 [Abstract] [Full Text] [Related]
13. Noncompromised penicillin-resistant pneumococcal pneumonia CBA/J mouse model and comparative efficacies of antibiotics in this model. Tateda K, Takashima K, Miyazaki H, Matsumoto T, Hatori T, Yamaguchi K. Antimicrob Agents Chemother; 1996 Jun; 40(6):1520-5. PubMed ID: 8726030 [Abstract] [Full Text] [Related]
14. Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor. Gross M, Clements J, Beckett RP, Thomas W, Taylor S, Lofland D, Ramanathan-Girish S, Garcia M, Difuntorum S, Hoch U, Chen H, Johnson KW. J Antimicrob Chemother; 2004 Mar; 53(3):487-93. PubMed ID: 14963065 [Abstract] [Full Text] [Related]